Navigation Links
Whistleblower Comments on Hawthorn Pharmaceuticals' $2.8 Million Settlement of His Medicaid Fraud Qui Tam Case
Date:3/28/2012

PLANO, Texas, March 28, 2012 /PRNewswire/ -- Hawthorn Pharmaceuticals Inc. and its parent company, Cypress Pharmaceutical Inc., have paid the federal government and certain states a total of $2.8 million to settle a whistleblower lawsuit filed by Phillips & Cohen LLP that alleged Hawthorn falsely marketed unapproved prescription drugs as being eligible for reimbursement by Medicaid and other government health care programs.

An even bigger result of the "qui tam" (whistleblower) lawsuit -- which was filed "under seal" in 2007 in Plano, Texas, and made public today -- was that government health care programs stopped purchasing unapproved Hawthorn prescription drugs during the government investigation of the whistleblower's claims. Those drugs included cough and cold drugs, hydrocodone products and timed-release products using unapproved "tannate" formulations of drug ingredients.

The whistleblower, Robert Heiden, is a former district sales manager for Hawthorn in Florida. He is represented by Phillips & Cohen LLP.

ROBERT HEIDEN, THE WHISTLEBLOWER: "The impact of this case goes beyond the money recovered. Unapproved and unsafe drugs sold by Hawthorn and other companies have been pulled off Medicaid and Medicare reimbursement lists, protecting consumers and saving taxpayers hundreds of millions of dollars."

"My case and the government's response mean that children, from infants to adolescents, now are protected from the dangers of certain drugs whose safety and effectiveness haven't been determined. With the removal of the drugs from government reimbursement lists, doctors are shielded from prescribing drugs they had been misled to believe were FDA-approved, and parents will no longer be giving their children drugs they didn't realize hadn't been approved by the FDA."

ATTORNEY COLETTE G. MATZZIE, PHILLIPS & COHEN LLP, WASHINGTON, DC: "A whistleblower lawsuit is a very effective enforcement tool for stopping sales of unapproved drugs. There are so many unapproved drugs that the FDA doesn't have the resources to stop sales of all of them. If the government cuts off Medicaid reimbursement for the unapproved drugs -- as it did with Hawthorn -- then the companies likely would no longer sell them as most of the market for the drugs would disappear."

ATTORNEY STEPHEN S. HASEGAWA, PHILLIPS & COHEN, SAN FRANCISCO: "It's appalling that a company would sell drugs for use by children, adolescents and others when those drugs hadn't been tested for safety or effectiveness. Doctors trusted that these drugs had been approved, not knowing Hawthorn knew how to work the system."

About the whistleblower case against Hawthorn

The settlement agreement -- which includes Hawthorn's chief executive officer, Max Draughn, a defendant in the case -- covers charges that Hawthorn caused false claims for three drugs used for skin problems -- Hylira, Zaclir, and Zacare Kit -- to be submitted to Medicaid and other government health programs from 2003 to 2009. The whistleblower lawsuit also raised safety concerns about certain cold and cough medications and many other unapproved prescription drugs Hawthorn was marketing.

The FDA issued a safety alert last year about certain unapproved prescription cough, cold and allergy products due to concerns about safety risks with use of those medications and asked drug companies to stop shipping those products for sale in the U.S.

Under the False Claims Act, whistleblowers are entitled to 15 percent to 25 percent of the amount recovered if the government joins their qui tam lawsuits and recovers funds. Heiden will receive 21 percent of the settlement amount for the information he provided and the work he and his attorneys did on the case.

Heiden praised Phillips & Cohen and the team of federal and state attorneys and investigators who worked on the case, in particular Assistant U.S. Attorney Kevin McClendon, Eastern District of Texas; Ann Williams, investigator with the U.S. Attorney's Office in the Eastern District of Texas; Brian McCabe, trial attorney with the Department of Justice's Civil Division; and Texas Assistant Attorneys General Paula Juba and Susan Miller.

Phillips & Cohen is the nation's most successful law firm representing whistleblowers. Its cases have recovered over $7 billion, and its whistleblower clients have received rewards totaling more than $730 million. See www.phillipsandcohen.com.


'/>"/>
SOURCE Phillips & Cohen LLP
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Prescription Drug Manufacturers Underpaid Medicaid Rebates, Federal and State Whistleblower Complaint Alleges
2. Whistleblower Lawyers Comment on New England Journal of Medicine Study
3. Whistleblower Doctor Comments on His Case that Helped Expose Illegal Marketing of Topamax
4. Whistleblower Kickback Case Against Alpharma Results In $42.5 Million Recovery for U.S. and States
5. Pfizer Whistleblower Named Years Most Influential Person In Business Ethics
6. Whistleblowers Attorney Says Pfizers Guilty Plea Today Opens New Chapter on Aggressive Enforcement of Pharma Companies
7. NCPA Comments on FTC Action Against CVS Caremark, Vows to Continue PBM Transparency Efforts
8. Lilly Comments on 2011 Financial Guidance and Announces 2012 Financial Guidance
9. K-V Pharmaceutical Company Comments on Recent Settlement With the Department of Justice
10. Rock Creek Pharmaceuticals Announces Completion of Medical Conferences on Anatablocâ„¢ Research, Comments on Research Presentation at American Thyroid Association Annual Meeting
11. K-V Pharmaceutical Comments on ACOG and SMFM Information Update Regarding 17-Alpha Hydroxyprogesterone Caproate - FDA-Approved Makenaâ„¢ and Compounded 17P
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/17/2017)... -- Edwards Lifesciences Corporation (NYSE: EW ), the ... and critical care monitoring, plans to announce its operating ... the market closes on Wednesday, February 1, 2017, and ... that day to discuss those results. To ... (201) 689-8037.  For 72 hours following the call, an ...
(Date:1/17/2017)... PUNE, India , Jan. 17, 2017  Market Research Future ... Global Endoscopy Devices Market is expected to reach USD 33.6 million ... 2016. Market Highlights ... The Global Endoscopy Devices Market has been examined as ... rate. Globally there is huge demand for endoscopy device in various ...
(Date:1/17/2017)... Research and Markets has announced the addition of the ... offering. ... global fluoropolymer market in the healthcare industry to grow at a ... Fluoropolymer Market in the Healthcare Industry 2016-2020, has been prepared based ... report covers the market landscape and its growth prospects over the ...
Breaking Medicine Technology:
(Date:1/17/2017)... ... 17, 2017 , ... Peoples Health is pleased to announce ... Dec. 1, 2016. Peoples Health, a Metairie-based Medicare Advantage company, serves more than ... to our provider network, and the addition will benefit our members in the ...
(Date:1/17/2017)... ... January 17, 2017 , ... A prescription medication bottle, pocket knife, luggage and ... to Cradle Product Design Challenge , the Cradle to Cradle Products Innovation Institute ... design challenges scheduled to run through early 2018. The challenges are presented by the ...
(Date:1/17/2017)... (PRWEB) , ... January 17, 2017 , ... Neil H. ... financial planning assistance to communities throughout the region, is launching a charity drive to ... disease is by far the deadliest killer in America, and is responsible for 1 ...
(Date:1/17/2017)... ... January 17, 2017 , ... SC&H Group, a leading ... a Principal in its IT Advisory Services practice . Rossi is the third ... market demand for strategic IT guidance grows, and the practice continues to expand.     , ...
(Date:1/17/2017)... ... January 17, 2017 , ... ... and eliminate cyber threats in real-time, today announced a strategic partnership with ... Selangor, Malaysia. Joining other Seceon partners, TechLab Security has become a strategic partner ...
Breaking Medicine News(10 mins):